Jordan Phillipps

Jordan Phillipps

Auto-generated profile, based on publicly available information

Jordan Phillipps

Department of Dermatology, Mayo Clinic, Jacksonville, Florida, USA, mayo.edu

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2022 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
GWGuihong Wan
Guihong Wan
NNNga Nguyen
Nga Nguyen
FLFeng Liu
Feng Liu
MDMia S. DeSimone
Mia S. DeSimone
BLBonnie W. Leung
Bonnie W. Leung
YSYevgeniy Semenov
Yevgeniy Semenov
Prognostic analysis for early-stage (stage I/II) melanomas is of paramount importance for customized surveillance and treatment plans. Since immune checkpoint inhibitors have recently been approved for stage IIB and IIC melanomas, prognostic tools to identify patients at high risk of recurrence have become even more critical. This study aims to assess the effectiveness of machine-learning algorithms in predicting melanoma recurrence using clinical and histopathologic features from Electronic Health Records (EHRs). We collected 1720 early-stage melanomas: 1172 from the Mass General Brigham healthcare system (MGB) and 548 from the Dana-Farber Cancer Institute (DFCI). We extracted 36 clinicopathologic features and used them to predict the recurrence risk with supervised machine-learning algorithms. Models were evaluated internally and externally: (1) five-fold cross-validation of the MGB cohort; (2) the MGB cohort for training and the DFCI cohort for testing independently. In the internal and external validations, respectively, we achieved a recurrence classification performance of AUC: 0.845 and 0.812, and a time-to-event prediction performance of time-dependent AUC: 0.853 and 0.820. Breslow tumor thickness and mitotic rate were identified as the most predictive features. Our results suggest that machine-learning algorithms can extract predictive signals from clinicopathologic features for early-stage melanoma recurrence prediction, which will enable the identification of patients that may benefit from adjuvant immunotherapy.

1 January 2024 in Case Reports in Rheumatology
Verified
Journal Article
Open access
JPJordan Phillipps
Jordan Phillipps
SMSehreen Mumtaz
Sehreen Mumtaz
JVJayesh Valecha
Jayesh Valecha
RSRupert O. Stanborough
Rupert O. Stanborough
FBFlorentina Berianu
Florentina Berianu
VMVikas Majithia
Vikas Majithia
SAPHO syndrome, a rare inflammatory disorder of bone, joints, and skin, is named based on the presence of synovitis, acne, pustulosis, hyperostosis, and osteitis. The hallmark of SAPHO syndrome includes osteoarticular and dermatologic manifestations, however, rarer associations with inflammatory bowel disease (particularly Crohn’s disease) have been documented. The literature on the relationship between SAPHO syndrome and inflammatory bowel disease (IBD), especially ulcerative colitis (UC), remains limited. We report an unusual case of SAPHO syndrome in a patient with UC. Chest x‐ray and MRI showed enlargement of the right first rib and adjacent sternum. Bone scintigraphy revealed hyperostosis and ankylosis of the costochondral junction, and bone biopsy revealed reactive bone and costal cartilage without findings of infection or malignancy. Complete resolution of symptoms was achieved 4 months after starting zoledronic acid without significant adverse events. The diagnosis of SAPHO syndrome in IBD patients is rare, even more so in UC patients, likely attributable to underdiagnosis given the clinical heterogeneity of SAPHO syndrome and overlap with the extra‐intestinal manifestation of IBD. Our treatment approach provides critical data to the underreported literature on diagnosis and managing SAPHO syndrome in UC.

1 January 2026 in Case Reports in Rheumatology
Verified
Journal Article
Open access
RMRenee Morecroft
Renee Morecroft
JPJordan Phillipps
Jordan Phillipps
VMVikas Majithia
Vikas Majithia
SMSehreen Mumtaz
Sehreen Mumtaz
Catastrophic antiphospholipid syndrome (CAPS) is a rare, life‐threatening variant of antiphospholipid syndrome (APS) characterized by rapid, widespread thrombosis leading to multiorgan failure. Affecting less than 1% of APS patients, CAPS is associated with a high mortality rate of 30%–50%, necessitating prompt diagnosis and aggressive treatment. The mainstay of management includes anticoagulation, high‐dose glucocorticoids, and plasma exchange or intravenous immunoglobulins, with biologic therapies such as rituximab and eculizumab reserved for refractory cases. We report a case of a 60‐year‐old male with a history of triple‐antibody–positive APS complicated by recurrent diffuse alveolar hemorrhage (DAH), adrenal hemorrhage, chronic kidney disease, and superficial vein thrombosis. His condition progressed to CAPS approximately 5 years prior with a course complicated by heparin‐induced thrombocytopenia. His condition stabilized with high‐dose corticosteroids and rituximab therapy with sustained symptomatic improvement after 10 months of rituximab. This case highlights the complexity of CAPS diagnosis and management, in the context of DAH, emphasizing the importance of early recognition, multidisciplinary care, and individualized treatment strategies. Our patient’s prolonged disease stabilization with rituximab underscores its potential role in long‐term CAPS management. Further research is needed to refine treatment protocols and improve outcomes for this rare but life‐threatening condition.

12 December 2025 in International Journal of Dermatology
Verified
Journal Article
Closed access
JPJordan Phillipps
Jordan Phillipps
RGRuifeng Guo
Ruifeng Guo
RMRenee Morecroft
Renee Morecroft
MSMD Sokumbi
MD Sokumbi

1 January 2026 in Case Reports in Hematology
Verified
Journal Article
Open access
RMRenee Morecroft
Renee Morecroft
ALAzalfa Lateef
Azalfa Lateef
JPJoseph Brandon Parker
Joseph Brandon Parker
RSRachel Sauls
Rachel Sauls
JPJordan Phillipps
Jordan Phillipps
SMSehreen Mumtaz
Sehreen Mumtaz
Introduction: T‐cell lymphomas are rare, comprising 10%–15% of non‐Hodgkin lymphomas (NHLs). Their etiology remains unclear, and pathophysiology varies widely among subtypes. Sarcoid‐like reactions (SLRs) have been reported in approximately 7.3% of NHLs, including T‐cell lymphomas, and can closely resemble sarcoidosis clinically/histologically. This overlap complicates diagnosis, particularly when secondary myelofibrosis—a rare and poorly understood complication—arises. Myelofibrosis has also been observed in sarcoidosis, further blurring the distinction between these entities. Treatment for T‐cell lymphoma‐associated secondary myelofibrosis is not standardized, with predominantly CHOP‐based regimens showing variable efficacy. This warrants further research to guide diagnostic and management frameworks. Case Description: We report the case of a 57‐year‐old male with known systemic sarcoidosis who developed recurrent symptomatic hypercalcemia and new‐onset transfusion‐dependent pancytopenia. Initial evaluation revealed bone marrow fibrosis with noncaseating granulomas, raising concern for sarcoidosis‐driven secondary myelofibrosis. However, repeat bone marrow biopsy demonstrated T‐cell lymphoma with a SLR. Primary myelofibrosis was excluded, supporting a secondary lymphoma‐driven process. The patient is currently undergoing treatment with BV‐CHP with close hematologic monitoring. Conclusion: T‐cell lymphoma‐associated SLR can closely mimic sarcoidosis and should be considered in the differential, particularly in patients with atypical presentations or cytopenias. Despite similar clinical and histological features, the underlying pathophysiology differs, necessitating thorough molecular and immunophenotypic evaluation. Though rare, this entity can lead to secondary myelofibrosis, underscoring the importance of excluding a primary myeloproliferative process. Further research is needed to define optimal therapy, with BV‐CHP representing a promising option in the evolving landscape of T‐cell lymphoma management.

4 November 2026 in International Journal of Dermatology
Verified
Journal Article
Closed access
JPJordan Phillipps
Jordan Phillipps
JRJorge A. Rios‐Duarte
Jorge A. Rios‐Duarte
LTLeila Tolaymat
Leila Tolaymat
HHHeather Hardway
Heather Hardway
NCNneka Comfere
Nneka Comfere
ADAddison Demer
Addison Demer